Search 

Meet Clyde Biosciences at the UK Pavilion (Hall B, Stand 2348).

Clyde Biosciences specialises in measuring and interpreting drug effects on cardiac cell function at clinically relevant doses. The company's proprietary technology combines a rang of human stem cell and other relevant in vitro phenotypes with a sensitive, data-rich measurement system and expert interpretation. The platform is demonstrable capable of screening-level throughout providing a more complete assessment of cardiovascular efficay and safety with in vivo and clinical preditability. 

Meet Cumulus Neuroscience at the UK Pavilion (Hall B, Stand 2348). 

Cumulus Neuroscience provides a reliable real-world multimodal digital data acquisition and analytics platform and end-to-end services and solutions for CNS clinical trials. Our platform is designed to be the gold-standard for CNS assessments, providing the critical data and insight needed for faster, more robust and cost-effective clinical trials that improve the delivery of new therapies to patients. We provide frequent at-home acquisition, combining neurophysiological monitoring (EEG) time-linked with a range of assessment tools, including cognition, mood, language and sleep. The frequent remote assessment significantly lowers patient burden and allows aggregation of multiple sessions to account for day-to-day cognitive fluctuation. Cumulus was formed in collaboration with leading global pharmaceutical companies to meet the industry’s complex clinical trial needs with a pharma advisory consortium, and Cumulus’ platform is currently deployed in clinical trials for neurodegeneration and neuropsychiatric diseases.

Meet Domainex at the UK Pavilion (Hall B, Stand 2348).

Domainex is a multi-award-winning integrated drug discovery research service partner, which provides the full range of pre-clinical drug discovery services. We work collaboratively in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world.  Our team comprises of over 90 scientists, who are committed to providing high quality services, and have expertise in:

• Protein production and characterisation
• Structural biology: X-ray crystallography and cryo-EM
• Assay development and screening (biochemical, biophysical and cell assays)
• High-throughput screening (HTS)
• Computational chemistry including virtual screening
• Medicinal, synthetic and analytical chemistry
• Fragment- and structure-based drug discovery

We have an excellent reputation; >80% of our clients signed up for extensions or additional studies in 2022 and >95% stated they would recommend us to someone in their professional network.

Meet Fusion Antibodies at the UK Pavilion (Hall B, Stand 2348).

Fusion Antibodies is a contract research organisation, which designs, and optimizes therapeutic antibodies for the healthcare market. We help clients solve complex, challenging problems throughout their early discovery antibody programs. Our expertise is defined by our experience. Unique process frameworks, and technology platforms, enable our clients to develop therapeutics within the most challenging modalities and diseases. Guiding clients through early-stage antibody discovery, in the most efficient and effective way, we enable biotechnology and pharmaceutical organizations towards their end-goal – the provision of treatments that improve the lives of patients worldwide.

As an independent team, we offer flexibility and agility that antibody discovery and development programs require. Our approach to projects considers long-term impacts on safety, efficacy, and manufacturability at every stage, de-risking antibody programs and maximizing success. As an early discovery partner, our scientists increase the pace to the clinic by guiding clients to develop the best antibodies possible.